Deal Details

GTCR Acquires Biocoat

Healthcare

GTCR, acquisition of Biocoat, a portfolio company of 1315 Capital

Summary

GTCR has acquired Biocoat Holdings, LLC (“Biocoat” or the “Company”), a portfolio company of 1315 Capital. Terms of the transaction were not disclosed.

Baird served as financial advisor to GTCR on this transaction.

About

Founded in 1980, GTCR is a leading private equity firm that pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $24 billion in over 270 companies, and GTCR currently manages over $27 billion in equity capital. GTCR is based in Chicago, Illinois with offices in New York, New York and West Palm Beach, Florida.

Founded in 1991 and headquartered in Horsham, Pennsylvania, Biocoat is a leading medical device contract manufacturing organization ("CMO"), specializing in custom, biocompatible hydrophilic coatings for interventional medical devices. The Company's capabilities include developing and supplying customized coatings formulations, performing coatings application services, and offering coatings equipment solutions. Over the past 31 years, Biocoat has developed a diverse base of both blue-chip and emerging medical device customers, a highly experienced team of engineers and scientists, and state-of-the-art manufacturing and R&D facilities. This platform enables the Company to work with its customers across a wide range of interventional products and medical device segments, including neurovascular, ophthalmology, cardiovascular and other interventional specialties.

1315 Capital is a private investment firm with over $925 million under management that provides expansion and growth capital to commercial-stage healthcare services, medical technology, therapeutics, and pharmaceutical services companies. 1315 Capital targets markets where high-quality management teams can rapidly scale platform companies into large and important businesses that positively impact patients, physicians, and the broader healthcare system.

Healthcare

GTCR, acquisition of Biocoat, a portfolio company of 1315 Capital